Skip to main content

Table 1 Backgrounds of patients

From: High neutrophils and low lymphocytes percentages in bronchoalveolar lavage fluid are prognostic factors of higher in-hospital mortality in diffuse alveolar hemorrhage

Variables All patients Survival Death p-value
Subject, n 68 50 18  
Demographics
Age, years 75 (72–80) 75 (71–80) 76 (74–80) 0.42
Males, n 49 (72%) 37 (74%) 12 (67%) 0.56
Comorbidities
Cardiac disease, n 49 (72%) 34 (68%) 15 (83%) 0.36
Respiratory disease, n 16 (24%) 12 (24%) 4 (22%) 1.00
Renal failure, n 4 (5.9%) 2 (4.0%) 2 (11%) 0.28
Malignancy, n 9 (13%) 6 (12%) 3 (17%) 0.69
Antithrombotic therapies
Antithrombotic therapy, n 48 (71%) 33 (66%) 15 (83%) 0.23
Antiplatelet drugs alone, n 7 (10%) 4 (8.0%) 3 (17%) 0.37
Anticoagulant drugs alone, n 23 (34%) 16 (32%) 7 (39%) 0.77
Antiplatelet and anticoagulant drugs, n 18 (26%) 13 (26%) 5 (28%) 1.00
Etiological diseases of DAH
Immune disease, n 6 (8.8%) 3 (6.0%) 3 (17%) 0.33
Drug-induced pneumonitis, n 4 (5.9%) 3 (6.0%) 1 (5.6%) 1.00
Heart failure, n 3 (4.4%) 1 (2.0%) 2 (11%) 0.17
Infection, n 9 (13%) 5 (10%) 4 (22%) 0.23
Other disease, n 9 (13%) 7 (14%) 2 (11%) 1.00
Idiopathic, n 37 (54%) 31 (62%) 6 (33%) 0.053
  1. Data presented as median (IQR) or absolute values (percentage)
  2. DAH diffuse alveolar hemorrhage, IQR interquartile range